Trends in initial primary treatment approach and biomarker testing across social determinants of health in early-stage non-small cell lung cancer
Disparities in early-stage NSCLC treatment by SDOH factors call for efforts to improve access to timely care for NSCLC.
Authors
- Ashwini Arunachalam (ORCID: https://orcid.org/0000-0003-4879-4770)
- Yu-Han Kao (ORCID: https://orcid.org/0000-0003-2416-4395)
- Hina Mohammed (ORCID: https://orcid.org/0000-0002-6600-961X)
- Ayman Samkari
- Chijioke Okeke (ORCID: https://orcid.org/0000-0003-0789-0942)
- Xiaohan Hu (ORCID: https://orcid.org/0000-0002-1263-5295)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Technology Holding (United States) (US)
- Weston Solutions (United States) (US)
- University of Houston (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-11-19
- DOI
- https://doi.org/10.1080/14796694.2025.2590002
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00